Clinical Research Management Briefing - May 29, 2018

Under the legislation, patients with terminal conditions will be able to bypass the Food and Drug Administration (FDA) to access experimental drug treatments.

The New York Times, May 22

New Cancer Treatments Lie Hidden Under Mountains of Paperwork

Gathering and deciphering medical records are some of the biggest barriers in one organization’s quest to create a database that links cancer treatment outcomes with medical information.

The New York Times, May 21

Regulatory

FDA Plans to Speed Path to Approval for Some Gene Therapies, Starting With Hemophilia

The hope that gene therapy will change how illnesses get treated will be tested as the FDA announces a new policy.

STAT, May 22

Financial and Operations

After Controversy Over Industry Funding, NIH Halts Enrollment in Moderate Drinking Study

With its reputation on the line, the National Institutes of Health (NIH) stopped enrollment until a thorough review of the study and its funding is completed.

STAT, May 17

Technology

Former FDA Commissioner Califf to Pharma: Opening Up on Health Data Requires Overcoming Risk

Patients are on board with their health data being collected – it’s the doctors and medical industry that need convincing.

MM&M, May 16

Pharm and Biotech

Why the Pharmaceutical Industry is Giving Up the Search for an Alzheimer’s Cure

The complexity of Alzheimer’s is causing major setbacks to pharmaceutical companies who are conducting research – all at a time when the number of older adults in the United States grows.

Quartz, May 20

Spotlight

Cloud Adoption Trends in Research Administration

Higher education and independent research institutions are benefiting by migrating their administrative software to cloud-based systems.

Huron

CSU Reduces Faculty Research Administrative Burden

In less than a year, Colorado State University (CSU) reduced its number of certifications per quarter by more than 1,000 with Huron’s Employee Compensation Compliance solution.

Huron